H.C. Wainwright raised its price objective on Nurix Therapeutics to $32.00 from $31.00 on Thursday and kept a Buy rating following the company’s fourth-quarter fiscal 2025 financial report. The firm’s revised target implies roughly 79% upside relative to Nurix’s prevailing share price of $17.87, and it is modestly above the broader analyst consensus average target of $27.70.
Nurix’s quarterly results showed a net loss of $0.82 per share, a slight improvement compared with H.C. Wainwright’s own estimate of a $0.84-per-share loss. The company remains unprofitable on a trailing-twelve-month basis, with InvestingPro data indicating a diluted EPS of -$2.97 over the last 12 months.
Revenue from collaboration and license arrangements for the quarter came in at $13.6 million, below H.C. Wainwright’s $15.0 million estimate. Research and development expenses were reported at $83.0 million for the quarter, beneath the research firm’s expectation of $87.8 million. Selling, general and administrative costs matched the firm’s projection at $13.6 million.
Nurix finished the quarter with about $592.9 million in cash and cash equivalents. H.C. Wainwright interprets that cash balance as sufficient to fund the company's operations into the second half of 2027. Supporting metrics from InvestingPro show a current ratio of 5.35 and indicate that Nurix’s liquid assets exceed its short-term obligations. The company’s market capitalization stood at $1.81 billion at the time of the report.
Several other research firms updated their views on Nurix in recent days. Morgan Stanley upgraded Nurix from Equalweight to Overweight and raised its price target sharply to $36.00 from $15.00, citing increased confidence in the company’s lead candidate, Bexdeg, as it moves toward pivotal development. RBC Capital raised its price target to $30.00 from $28.00 and maintained an Outperform rating, while describing the reported quarter as "uneventful." BTIG reiterated a Buy rating with a $30.00 price target, noting Nurix’s cash position and progress across key programs.
Nurix has outlined objectives for 2026 centered on advancing its BTK degrader, Bexdeg. The company plans to move Bexdeg into pivotal development for relapsed/refractory chronic lymphocytic leukemia, including execution of a Phase 2 study and initiation of a confirmatory Phase 3 trial aimed at supporting global registration. Additionally, Nurix intends to broaden Bexdeg’s development into autoimmune and inflammatory indications with a new tablet formulation and targets an IND submission for that formulation in 2026.
InvestingPro data cited in the company’s reporting indicates that Nurix is trading close to its Fair Value. The mix of an improving but still negative EPS trend, a cash runway that extends into mid-2027 by H.C. Wainwright’s measure, and the active clinical development plan for Bexdeg frame the company’s current position: a biotech with ongoing development milestones and a significant cash cushion despite not yet reaching profitability.
Contextual note: The figures and analyst ratings above reflect the company’s disclosed fourth-quarter fiscal 2025 results and subsequent analyst reactions. The information presented here follows the reported data and the stated viewpoints of the named research firms.